← Back to Clinical Trials
Recruiting NCT06667232

NCT06667232 Evaluating Modulation Effects of Burst Stimulation Patterns Using SEEG

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06667232
Status Recruiting
Phase
Sponsor Xuanwu Hospital, Beijing
Condition Epilepsy
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-01-18
Primary Completion 2025-12-25

Eligibility & Interventions

Sex All sexes
Min Age 14 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Single-pulse stimulationPaired-pulse stimulationStepwise frequency stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-01-18 with a primary completion date of 2025-12-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study aims to evaluate modulation effects of burst stimulation patterns via SEEG.

Eligibility Criteria

Inclusion Criteria: * Drug-resistant focal epilepsy * Justified SEEG exploration in the context of presurgical assessment of epilepsy * Subjects will be a part of the epilepsy-monitoring unit for long-term SEEG recordings and analysis * Written non-opposition to study participation Exclusion Criteria: * Pregnant women (Contraindication to SEEG exploration) * Psychiatric disorders * History of psychotic disorders * History of cranial trauma serious (according to the classification), previous or evolutionary other neurological pathology * Subjects that experience surgical complications during the implant procedure will be excluded from the study

Contact & Investigator

Central Contact

Liankun Ren, MD

✉ renlk2022@outlook.com

📞 +86 13681576621

Principal Investigator

Liankun Ren, MD

PRINCIPAL INVESTIGATOR

Xuanwu Hospital, Beijing

Frequently Asked Questions

Who can join the NCT06667232 clinical trial?

This trial is open to participants of all sexes, aged 14 Years or older, up to 65 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06667232 currently recruiting?

Yes, NCT06667232 is actively recruiting participants. Contact the research team at renlk2022@outlook.com for enrollment information.

Where is the NCT06667232 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06667232 clinical trial?

NCT06667232 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Liankun Ren, MD at Xuanwu Hospital, Beijing. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology